INDICATIONS
Sacubitril/valsartan (LCZ696) is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (New York Heart Association [NYHA] class II to IV) and reduced ejection fraction. [1] [2] [3] [4] Sacubitril/ valsartan can be used concurrently with other heart failure therapies in place of an angiotensin converting enzyme (ACE) inhibitor or other angiotensin II receptor blocker (ARB). 4 Sacubitril/valsartan has also been studied for the treatment of essential hypertension in adult patients. [5] [6] [7] It is currently being compared head to head with olmesartan in patients 60 years and older to determine the effects on aortic stiffness and central aortic hemodynamics in the PARAMETER study. This 52-week trial is assessing the impact of these drugs on central aortic systolic pressure and pulse pressure; results are expected in 2015. 8 Preliminary work is also being conducted to determine whether sacubitril/ valsartan has a potential role in modulating cardiac remodeling after a myocardial infarction (MI). 9 Neprilysin is an enzyme expressed in the kidney that is responsible for the degradation of several endogenous substances, including C-type natriuretic peptide, atrial natriuretic peptide, B-type natriuretic peptide (BNP), endothelin-1, kinin peptides, opioid peptides, substance P, amyloid beta protein, gastrin, and angiotensin I. 12 Natriuretic peptides (types A and B) promote vasodilation and natriuresis, inhibit abnormal growth of the ventricles, suppress the renin-angiotensinaldosterone system (RAAS) and sympathetic nervous system, inhibit the release and action of vasopressin, and augment the parasympathetic nervous system. 13 Accumulation of some of these substances reduces blood pressure and theoretically improves cardiovascular outcomes. 12 Sacubitril (AHU377) is a prodrug of LBQ657, which is a neprilysin inhibitor. 14 Angiotensin II is a pressor agent from the RAAS with effects that include release of aldosterone, cardiac stimulation, and reabsorption of sodium in the kidneys. These 3 mechanisms lead to elevated blood pressure. Valsartan blocks the binding of angiotensin II to the angiotensin II type 1 receptor, leading to a decrease in blood pressure. 11 Administration of multiple doses of sacubitril/ valsartan (a fused molecule that contains 1:1 molar ratio of valsartan and sacubitril) leads to increases in plasma cyclic guanosine monophosphate, renin concentration and activity, and angiotensin II. 5, 14, 15 The clinical relevance of the changes in neurohormone concentrations is not clear, although a relationship between baseline plasma renin and reduction in mean diastolic blood pressure (DBP) was observed. 5 In a clinical trial of patients with heart failure with preserved ejection fraction (HFpEF) (diastolic heart failure), sacubitril/valsartan treatment caused a reduction in high-sensitivity troponin, which was associated with improved cardiac structure, myocardial injury, n-terminal prohormone brain natriuretic peptide (NT-proBNP), and left atrial size. 16 
PHARMACOKINETICS
After oral administration of the sacubitril/valsartan tablet, the compound dissociates into sacubitril and valsartan. The time to maximum plasma concentration following a single dose of sacubitril/valsartan is 1.5 to 2.2 hours for valsartan, 0.5 to 1.1 hours for sacubitril, and 1.9 to 3.5 hours for LBQ657. 4, 14 The oral bioavailability of sacubitril is 60% or greater. Valsartan in this formulation has better bioavailability than valsartan in other marketed tablet formulations; equivalent doses for valsartan 26, 51, and 103 mg in the Entresto tablets would be 40, 80, and 160 mg tablets, respectively, with other marketed tablet formulations. 4, 14 Administration with food had no clinically meaningful effects on the systemic exposures of sacubitril, LBQ657, or valsartan; there is a decreased systemic exposure to valsartan when administered with food but it had no effect on the drug's therapeutic effect. 4 All 3 compounds (sacubitril, LBQ657, and valsartan) are highly bound (94% to 97%) to plasma protein.
The apparent volume of distribution is 103 L for sacubitril and 75 L for valsartan. The ability of LBQ657 to cross the blood-brain barrier is poor (0.28%). 4 Sacubitril is converted to LBQ657 by esterases. LBQ657 is not metabolized and valsartan undergoes minimal metabolism (20%). Urinary excretion of sacubitril (mainly as LBQ657) is 52% to 68% of the oral dose and is approximately 13% for valsartan and its metabolites. The portion of the dose found in the feces for sacubitril (mainly as LBQ657) is 37% to 48%; for valsartan and its metabolites, it is 86%. 4 Mean half-life of each compound was 1.1 to 3.6 hours for sacubitril, 9.9 to 11.1 hours for LBQ657, and 8.9 to 16.6 hours for valsartan. 4, 14 Steady-state concentrations are achieved in 3 days with twice-daily oral administration. 4 Both the maximal drug concentration (C max ) and area under the curve (AUC) exhibit an approximately linear relationship with increased dose; peak plasma concentration occurs at 1.6 to 4.9 hours for valsartan, 0.6 to 0.9 hours for sacubitril, and 1.8 to 2.7 hours for LBQ657 with repeated daily dosing. 14 No accumulation was reported after 14 days of dosing for either valsartan or sacubitril, but LBQ657 has minimal accumulation. 4, 14 Gender had no effect on the pharmacokinetics of sacubitril/valsartan, but pharmacokinetics of LBQ657 and valsartan were different between younger (18 to 45 years of age) and older subjects (older than 65 years). When compared to younger patients, LBQ657 kinetics in the elderly population demonstrated a 42% increase in AUC and a 30% increase in half-life; peak plasma concentrations were unaffected by age. Increases were also observed in the elderly for valsartan kinetic parameters, including AUC (30%), peak plasma concentration (24%), and half-life (3.35 hours). However, none of these differences were considered clinically significant and did not warrant an adjustment in dose. 17
COMPARATIVE EFFICACY Indication: Treatment of Chronic Heart Failure with Reduced Ejection Fraction
Entresto contains sacubitril (24 mg, 49 mg, or 97 mg) and valsartan (26 mg, 51 mg, or 103 mg). Dosing in clinical trials was based on the total amount of both components (ie, 24/26 mg, 49/51 mg, and 97/103 mg were referred to as 50 mg, 100 mg, and 200 mg, respectively). The dose in approved product labeling lists the milligram strength of the individual components of the combination tablet: sacubitril 24 mg/valsartan 26 mg, sacubitril 49 mg/valsartan 51 mg, and sacubitril 97 mg/valsartan 103 mg. To reduce the risk of errors, include the doses of both ingredients (eg, Entresto 24/26 mg) when prescribing Entresto. 4
Guidelines: 2013 American College of Cardiology Foundation/American Heart Association (ACCF/AHA) Task Force guideline for the management of heart failure: A report of the ACCF/AHA Task Force on Practice Guidelines
Reference: Yancy and enalapril patients, respectively, maintained the target dose through the end of the study. 20 • Incidence of symptomatic hypotension was 14% with sacubitril/valsartan and 9.2% with enalapril (P < .001); number needed to harm (NNH) with sacubitril/valsartan was 20.8. • Incidence of serum creatinine elevated to at least 2.5 mg/dL was 3.3% with sacubitril/valsartan and 4.5% with enalapril (P = .007); NNH with enalapril was 83.3. • Incidence of serum potassium greater than 6 mmol/L was 4.3% with sacubitril/valsartan and 5.6% with enalapril (P = .007); NNH with enalapril was 76.9. • Incidence of cough was 11.3% with sacubitril/ valsartan and 14.3% with enalapril (P < .001); NNH with enalapril was 33.3. • Post hoc analysis: Risk of death or hospitalization for any reason was lower with sacubitril/ valsartan compared with enalapril (HR, 0.87; 95% CI, 0.82 to 0.93; P < .0001). 20 • Post hoc analysis: Proportion of patients requiring addition of new drug, intravenous (IV) therapy, or increased daily dose of diuretic for longer than 1 month was 12.4% with sacubitril/ valsartan and 14.3% with enalapril (HR, 0.84; 95% CI, 0.74 to 0.94; P = .003); NNT with sacubitril/valsartan was 52.7. • Post hoc analysis: Proportion of patients evaluated in the emergency department for worsening heart failure but discharged without admission was 2.4% with sacubitril/valsartan and 3.6% with enalapril (HR, 0.66; 95% CI, 0.52 to 0.85; P = .001); NNT with sacubitril/valsartan was 83.4. Comments: This was a phase 3 pivotal trial of clinically stable patients with mild to moderate heart failure. If patients were not tolerating either study drug, the dose could be reduced after discontinuation of drugs with no disease-modifying effects (eg, calcium channel blockers, nitrates, alpha-ARBs). Because a greater proportion of the enalapril group was expected to receive a beta-blocker and mineralcorticoid antagonist, the sample size was based on expected annual composite event rate of 14.5% and cardiovascular death rate of 7%. Predefined subgroup analysis showed improvement in the primary endpoint in all regions/races except Black, Asian, or Native American patients and patients in Western Europe or Asia-Pacific regions. Additional subgroups showing no benefit compared with enalapril were patients with NYHA class III or IV, ejection fraction more than 35%, no prior use of an ACE inhibitor, and age 75 years and older. Rates of adverse events are summarized elsewhere. Number of days in the hospital per admission per patient did not significantly differ (P = .86), although both the number of patients and the total number of stays in intensive care were significantly lower with sacubitril/valsartan compared with enalapril (P = .019 and P = .005, respectively). Post hoc analysis of the SOLVD-Treatment and CHARM-Alternative trials showed a greater reduction (43% relative risk; 95% CI, 34% to 50%; P < .0001) in the primary outcome with sacubitril/valsartan compared with placebo. 22 Issues surrounding the use of a putative placebo comparison exist, including major differences between trials (eg, background medications) and current guideline recommendations supporting an ACE inhibitor or ARB as the standard of care in almost all patients with heart failure. The guidelines recommend an ARB if the patient is unable to tolerate the ACE inhibitor (eg, due to cough), unless there is a contraindication to its use. 10 Enalapril was selected as the active comparator because it was used in the pivotal mortality/morbidity SOLVD-Treatment trial, which established the usefulness of ACE inhibitors in the treatment of patients with HFrEF and because the impact of ARBs on mortality was inconsistent at the time the PARADIGM-HF study was designed. 13, 18 Sacubitril was not combined with enalapril because the concurrent use of a neprilysin inhibitor (eg, sacubitril) with an ACE inhibitor increases the risk of angioedema; however, the combination of valsartan and sacubitril produced a lower risk of angioedema. A potential problem with ACE inhibitors (eg, enalapril) is that they may lose efficacy over time due to redundant angiotensin II-generating pathways, sometimes referred to as "aldosterone escape" pathways, whereas ARBs do not possess the bradykinin-enhancing properties of ACE inhibitors. As previously mentioned, patients without a history of ACE inhibitor use showed no added benefit for the primary endpoint. Limitations: Less than 10% of patients included were located in North America.
Drug: Sacubitril/Valsartan vs Valsartan
Reference: Solomon 
Endpoint(s):
Proportion of patients achieving the target dose was 81% in the sacubitril/valsartan group and 78% in the valsartan group. Most commonly reported adverse events were symptomatic hypotension, hyperkalemia, and renal dysfunction. Comments: This was a phase 2 study. Patients were analyzed as an intent-to-treat (ITT) population at 12 weeks, but week 36 data were analyzed for completers. Completer analysis of the primary endpoint showed similar results to ITT analysis. Missing data were handled with last observation carried forward. Patients were stratified by previous use of an ACE inhibitor or ARB and by region. Patients with HFpEF showed a reduction in a biomarker that is correlated with improvements in left ventricular wall stress. Monitoring of NT-proBNP is recommended as a prognostic factor. 10 A post hoc analysis found a weak correlation between reductions in SBP and NT-proBNP. 24 The study was too short to measure clinical outcomes. Limitations: The study was not powered or designed to show clinical outcomes. The majority of patients enrolled had NYHA class II heart failure. Formulary Drug Reviews corresponding valsartan doses. All reductions in blood pressure are placebo subtracted. This was a surrogate marker study rather than an outcome study. Safety data did not show evidence of angioedema, although a relatively small number of Black patients were enrolled. Kidney function was better preserved, as indicated by statistical differences in estimated GFR and cystatin C; an increase in urinary albumin to creatinine ratio was seen with sacubitril/valsartan compared with valsartan. 25 Limitations: The study did not include a large number of Black patients (6% to 11% in each group).
Indication: Other Cardiovascular Disease

Drug: Sacubitril/Valsartan vs Placebo
Reference: Kario 24 -hour blood pressure control at 8 weeks was improved for each dose of sacubitril/valsartan compared with placebo (P < .0001); these results were similar for daytime and nighttime blood pressure control. • Increase in DBP after 1 week of single-blind placebo was 8, 8.8, and 11.6 mm Hg for sacubitril/ valsartan 100, 200, and 400 mg, respectively. Endpoint(s): The most commonly reported adverse events were nasopharyngitis and upper respiratory tract infection. Comments: This phase 2 trial evaluating reduction of blood pressure with sacubitril/valsartan in an Asian population confirmed results of another study with a predominantly White population. 2 Reductions were compared with placebo only, rather than with an equivalent dose of valsartan. Many therapeutic options are available for the treatment of hypertension, and interruption of the RAAS is not as effective for Asian patients. A head-to-head comparison with an agent of another class would confirm the efficacy of sacubitril/valsartan for the treatment of hypertension. Safety results do not show any new concerns, although the duration of the trial was relatively short. Limitations: The trial lacked an active comparator.
CONTRAINDICATIONS, WARNINGS, AND PRECAUTIONS Contraindications
Sacubitril/valsartan is contraindicated in patients with hypersensitivity to any component of the 
Warnings and Precautions
Sacubitril/valsartan carries a boxed warning regarding the risk of fetal toxicity.
Sacubitril/valsartan therapy should be discontinued when pregnancy is detected. 4 Use of drugs acting on the RAAS during the second and third trimesters of pregnancy may lead to increased fetal and neonatal death. 4, 11 Sacubitril/valsartan should also be avoided during lactation; if used, breast-feeding should be discontinued. 4 There is a risk of angioedema with sacubitril/ valsartan. Prior to initiation of sacubitril/valsartan, patients should discontinue therapy with the ACE inhibitor at least 36 hours prior to initiating sacubitril/valsartan. The risk of angioedema is also higher in Black than in non-Black patients. Patients with a history of angioedema, especially to previous ACE inhibitor or ARB therapy, may be at increased risk. 4, 13 Hypotension leading to dizziness or falls may occur in patients taking sacubitril/valsartan. In patients with volume or salt depletion, correct these depletions prior to initiation with sacubitril/valsartan or start sacubitril/valsartan therapy at a lower dose. If the patient is receiving diuretics, concomitant antihypertensive drugs, or treatment of other causes of hypotension, the dose of these medications should be evaluated and adjusted, if necessary. If hypotension persists after these changes, the dose of sacubitril/valsartan may need to be adjusted again or temporarily discontinued. 4, 11 Some patients may be at increased risk of decreased renal function. These patients may have preexisting renal artery stenosis, chronic kidney disease, or severe congestive heart failure. Careful monitoring of patients with these conditions is necessary to reduce the incidence of acute renal failure, and dosage adjustments or interruption of therapy may be necessary. 4, 11 Patients with impaired renal function, diabetes, hypoaldosteronism, or a high-potassium diet who are taking valsartan-containing products may be at increased risk of hyperkalemia. If a patient experiences hyperkalemia, a reduction in dosage or interruption of sacubitril/valsartan may be required. 4, 11 Use in patients with severe hepatic impairment is not recommended. 4 Safety and effectiveness in pediatric patients have not been established. 4
ADVERSE REACTIONS
The mostly commonly reported adverse reactions (occurring in 5% or more of patients) were hypotension, hyperkalemia, cough, dizziness, and renal failure. 4 The most commonly reported adverse reactions in published clinical trials of patients treated for heart failure with sacubitril/valsartan or enalapril, respectively, were hypotension (17.6% vs 12%), cardiac failure (17.4% vs 19.7%), hyperkalemia (11.6% vs 14%), renal impairment (10.1% vs 11.5%), cough (8.8% vs 12.6%), and dizziness (6.3% vs 4.9%). 18 Other adverse events included atrial fibrillation, pneumonia, peripheral edema, dyspnea, nasopharyngitis, upper respiratory tract infection, urinary tract infection, diarrhea, bronchitis, angina pectoris, anemia, back pain, influenza, hypokalemia, chronic cardiac failure, congestive heart failure, arthralgia, hypertension, fatigue, diabetes mellitus, gout, renal failure, hyperuricemia, ventricular tachycardia, noncardiac chest pain, headache, acute renal failure, syncope, chronic obstructive pulmonary disease, insomnia, pain in extremity, asthenia, nausea, death from a cardiovascular event, constipation, pyrexia, acute cardiac failure, and vomiting. 4, 18 
DRUG INTERACTIONS
Use with an ACE inhibitor or other ARB will cause a dual blockade of the renin-angiotensin system and should be avoided. Aliskiren should be avoided in patients with diabetes or patients with renal impairment (estimated GFR less than 60 mL/min/1.73 m 2 ). 4 Sacubitril/valsartan plus a potassium-sparing diuretic may increase serum potassium levels. Patients requiring dual therapy with these drugs should have their serum potassium level monitored regularly throughout therapy. 4 Concurrent use with NSAIDs may increase the risk of developing renal impairment. 4 The addition of sacubitril/valsartan to lithium may result in increased lithium levels and lithiumrelated toxicities. 4 Sacubitril/valsartan is a weak inhibitor of cytochrome P450 (CYP-450) 2C9. Warfarin, a drug commonly used in patients with heart failure, is a substrate of CYP2C9. A drug-drug interaction study showed no Formulary Drug Reviews significant increase in the exposure of warfarin 25 mg or significant increases in partial thromboplastin time and international normalized ratio. Additionally, no effects on the pharmacokinetics of sacubitril/valsartan 200 mg (sacubitril 97 mg/valsartan 103 mg) twice daily were reported. No adjustment is required when coadministering sacubitril/valsartan and warfarin. 26 Coadministration of sacubitril/valsartan 400 mg (2 doses of sacubitril 97 mg/valsartan 103 mg) once daily and carvedilol 25 mg twice daily decreased the peak plasma concentrations of valsartan by 12% but did not affect the pharmacokinetics of sacubitril or carvedilol. No adjustment should be required when coadministering sacubitril/valsartan and carvedilol. 27 Coadministration of sacubitril/valsartan 400 mg (2 doses of sacubitril 97 mg/valsartan 103 mg) once daily and metformin 1,000 mg once daily in Japanese patients decreases both the peak plasma concentrations and total exposure of metformin by 23% but does not affect the pharmacokinetics of sacubitril/ valsartan. None of these changes were considered clinically relevant. 28, 29 Coadministration of sacubitril/valsartan 200 mg (sacubitril 97 mg/valsartan 103 mg) twice daily with digoxin 0.25 mg once daily did not affect the pharmacokinetics of sacubitril/valsartan or digoxin. No dose adjustment of either drug should be required when coadministering sacubitril/valsartan and digoxin. 30 Coadministration of sacubitril/valsartan 400 mg (2 doses of sacubitril 97 mg/valsartan 103 mg) as a single dose or once daily with omeprazole 40 mg once daily in healthy Japanese subjects did not alter the AUC of sacubitril and the pharmacokinetics of LBQ657, but did decrease the peak plasma concentrations of sacubitril by 7% and the AUC and peak plasma concentrations of valsartan by 11% and 13%, respectively. None of these changes were considered clinically relevant. 29 Coadministration of sacubitril/valsartan 400 mg (2 doses of sacubitril 97 mg/valsartan 103 mg) as a single dose or once daily with levonorgestrel 150 mcg/ ethinyl estradiol 30 mcg in healthy Japanese subjects had no effect on the pharmacokinetics of ethinyl estradiol and LBQ657, no effect on the AUC of levonorgestrel, decreased the C max of levonorgestrel by 15%, and decreased the AUC and C max of valsartan by 14% and 16%, respectively. None of these changes were considered clinically relevant. 29
RECOMMENDED MONITORING
Routine monitoring of blood pressure, NYHA class function, kidney function, and serum electrolytes should be performed. 18 Additional monitoring for worsening symptoms (eg, jugular venous pressure, peripheral edema, orthopnea) is recommended by guidelines; baseline measurement of BNP or NT-proBNP may help determine prognosis. 10 Reductions in NT-proBNP were seen in 1 trial, but the clinical significance of serial NT-proBNP has not been determined. 10, 23 
DOSING
The recommended starting dose for the treatment of heart failure is sacubitril 49 mg/valsartan 51 mg twice daily with or without food. The dose should be doubled after 2 to 4 weeks to sacubitril 97 mg/valsartan 103 mg twice daily (target maintenance dose), as tolerated by the patient. 4 The starting dose should be reduced to sacubitril 24 mg/valsartan 26 mg twice daily for patients not currently taking an ACE inhibitor or ARB or who were previously taking a low dose of these agents, for patients with severe renal impairment (estimated GFR less than 30 mL/min/1.73 m 2 ), and for patients with moderate hepatic impairment. The dose should be doubled in these patients every 2 to 4 weeks until the target maintenance dose is reached, if tolerated by the patient. 4 If the patient is being switched from an ACE inhibitor, the ACE inhibitor should be discontinued and the first dose of sacubitril/valsartan administered at least 36 hours after the last dose of the ACE inhibitor. 4 No dosage adjustment is needed for patients with mild hepatic impairment or in those with mild or moderate renal impairment. 4 For the treatment of hypertension (not an approved indication), daily sacubitril 49 mg/valsartan 51 mg did not significantly affect blood pressure beyond the reduction achieved with valsartan 80 mg; therefore, the daily dose may be sacubitril 97 mg/ valsartan 103 mg once daily. 5, 6 PRODUCT AVAILABILITY Sacubitril/valsartan was approved for the treatment of heart failure on July 7, 2015. 1, 2 The product is available as an unscored, ovaloid, film-coated tablet in 3 different strengths (sacubitril 24 mg/valsartan 26 mg, sacubitril 49 mg/valsartan 51 mg, and sacubitril 97 mg/valsartan 103 mg) in bottles containing 60 or 180 tablets and blister packages of 100. 4 The tablets should be stored in their original packaging and protected from moisture at 25°C (77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). 4 
